{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:14:23Z","timestamp":1778210063677,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-025-04964-5","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T01:52:07Z","timestamp":1769565127000},"page":"9913-9921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US\u2011approved denosumab reference products in healthy adult men"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-6371","authenticated-orcid":false,"given":"Steve","family":"Fenwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhi","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naman","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrikrishna","family":"Kolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4964_CR1","first-page":"469","volume":"6","author":"EA Blackstone","year":"2013","unstructured":"Blackstone EA, Joseph PF (2013) The economics of biosimilars. Am Health Drug Benefits 6:469\u2013478","journal-title":"Am Health Drug Benefits"},{"key":"4964_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342. https:\/\/doi.org\/10.1038\/nature01658","journal-title":"Nature"},{"key":"4964_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"4964_CR4","unstructured":"European Medicines Agency (2014) European Medicines Agency. Guideline on similar biological medicinal product. https:\/\/www.ema.europa.eu\/en\/documents\/ scientific-guideline\/guideline-similar-biological-medicinal-products -rev1_en.pdf3."},{"key":"4964_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00198-022-06573-x","volume":"34","author":"S Fenwick","year":"2023","unstructured":"Fenwick S, Vekariya V, Patel R et al (2023) Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women. Osteoporos Int 34:179\u2013188. https:\/\/doi.org\/10.1007\/s00198-022-06573-x","journal-title":"Osteoporos Int"},{"key":"4964_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"4964_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304","journal-title":"J Clin Oncol"},{"key":"4964_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi A, Vojdanian M, Soroush M et al (2022) Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther 24:161. https:\/\/doi.org\/10.1186\/s13075-022-02840-8","journal-title":"Arthritis Res Ther"},{"key":"4964_CR9","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"4964_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00223-004-0287-6","volume":"75","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, Oden A et al (2004) Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 75:90\u201399. https:\/\/doi.org\/10.1007\/s00223-004-0287-6","journal-title":"Calcif Tissue Int"},{"key":"4964_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14712598.2024.2316846","volume":"24","author":"A Kim","year":"2024","unstructured":"Kim A, Hong JH, Shin W et al (2024) A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT-P41 and reference denosumab in healthy males. Expert Opin Biol Ther 24:655\u2013663. https:\/\/doi.org\/10.1080\/14712598.2024.2316846","journal-title":"Expert Opin Biol Ther"},{"key":"4964_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"T Kvien","year":"2022","unstructured":"Kvien T, Patel K, Strand V (2022) The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum 52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009","journal-title":"Semin Arthritis Rheum"},{"key":"4964_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/13543784.2023.2273510","volume":"32","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim S, Seo H, Kim S (2023) A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects. Expert Opin Investig Drugs 32:959\u2013966. https:\/\/doi.org\/10.1080\/13543784.2023.2273510","journal-title":"Expert Opin Investig Drugs"},{"key":"4964_CR14","unstructured":"Prolia Summary of Product Characteristics. Available at https:\/\/www.medicines.org.uk\/emc\/product\/568\/smpc"},{"key":"4964_CR15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","volume":"38","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4-9. https:\/\/doi.org\/10.1016\/j.bone.2005.11.024","journal-title":"Bone"},{"key":"4964_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70013","volume":"17","author":"M Tomaszewska-Kiecana","year":"2024","unstructured":"Tomaszewska-Kiecana M, Carapu\u00e7a E, Florez-Igual A, Queiruga-Parada J (2024) MB09, a denosumab biosimilar candidate: biosimilarity demonstration in a phase I study in healthy subjects. Clin Transl Sci 17:e70013. https:\/\/doi.org\/10.1111\/cts.70013","journal-title":"Clin Transl Sci"},{"key":"4964_CR17","unstructured":"US Food and Drug Administration (2011) Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125320. Accessed 11 June 2025"},{"key":"4964_CR18","unstructured":"US Food and Drug Administration (2015) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. https:\/\/www.fda.gov\/media\/82647. Accessed 11 June 2025"},{"key":"4964_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14712598.2024.2308645","volume":"24","author":"B Vogg","year":"2024","unstructured":"Vogg B, Poetzl J, El Galta R et al (2024) Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males. Expert Opin Biol Ther 24:91\u2013100. https:\/\/doi.org\/10.1080\/14712598.2024.2308645","journal-title":"Expert Opin Biol Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04964-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:44:13Z","timestamp":1778208253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04964-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4964"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04964-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Riddhi Medical Nursing Home Institutional Ethics Committee (RMNH IEC) on 24th August 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consents"}},{"value":"S.F. is an employee of Accord Healthcare V.P. is an employee of Intas Pharmaceuticals N.S., R.P., P.K. and S.K. are employees of Lambda Therapeutic Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}